TEZSPIRE: payments to doctors
Payments that named TEZSPIRE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $23.3M
- Providers
- 21,547
- Transactions
- 205,244
- Average per transaction
- $113
The per-transaction average — $113 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 21,547 providers the average total is $1,080, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $19,315,555 | 83.0% |
| Amgen | $3,866,843 | 16.6% |
| Astrazeneca UK Limited | $62,651 | 0.3% |
| Astrazeneca AB | $24,347 | 0.1% |